Rational analysis of the use of antiemetic drugs in tumor chemotherapy patients in our hospital

REN Danjun; ZHANG Juanli; LIU Meiyou; DING Likun; FAN Tingting; ZHANG Di; WANG Jingwen; WEN Aidong

doi:10.6039/j.issn.1001-0408.2024.12.14

您当前的位置：

首页 >

文章列表页 >

Rational analysis of the use of antiemetic drugs in tumor chemotherapy patients in our hospital

更新时间：2024-06-25

- Rational analysis of the use of antiemetic drugs in tumor chemotherapy patients in our hospital
- ZHONGGUO YAOFANG Vol. 35, Issue 12, Pages: 1495-1499(2024)
- 作者机构：
  
  空军军医大学第一附属医院，西安　710032
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.14
  CLC： R975+.4
- Published：30 June 2024，
  
  Received：13 November 2023，
  
  Revised：20 May 2024，
扫描看全文
任丹君,张娟利,刘美佑等.我院肿瘤化疗患者止吐药物使用的合理性分析 ^Δ[J].中国药房,2024,35(12):1495-1499.

REN Danjun,ZHANG Juanli,LIU Meiyou,et al.Rational analysis of the use of antiemetic drugs in tumor chemotherapy patients in our hospital[J].ZHONGGUO YAOFANG,2024,35(12):1495-1499.
任丹君,张娟利,刘美佑等.我院肿瘤化疗患者止吐药物使用的合理性分析 ^Δ[J].中国药房,2024,35(12):1495-1499. DOI： 10.6039/j.issn.1001-0408.2024.12.14.

REN Danjun,ZHANG Juanli,LIU Meiyou,et al.Rational analysis of the use of antiemetic drugs in tumor chemotherapy patients in our hospital[J].ZHONGGUO YAOFANG,2024,35(12):1495-1499. DOI： 10.6039/j.issn.1001-0408.2024.12.14.

摘要

目的

为肿瘤化疗患者合理使用止吐药物提供参考。

方法

利用医院信息系统收集2022年10月1日－11月30日我院肿瘤科、放疗科、妇科、消化科等9个科室使用止吐药物的肿瘤化疗患者资料，统计患者化疗药物和止吐药物的使用情况，并分析止吐药物不合理用药情况。

结果

共纳入520例患者，有248例患者（47.69%）使用的化疗药物致吐风险等级为中度，135例患者（25.96%）为高度。520例患者共使用5-羟色胺3受体拮抗剂461例次（73.06%），包括帕洛诺司琼333例次、昂丹司琼106例次、托烷司琼15例次、格拉司琼7例次，其中优先使用国采药品及国家基本药物的患者仅148例次（32.10%）；使用神经激肽1受体拮抗剂共170例次（26.94%），包括福沙匹坦112例次、阿瑞匹坦58例次。162例患者（31.15%）的止吐药物使用不合理；不合理用药类型中，以止吐方案不合理最多（22.40%），其次为药物经济性不合理（19.13%）。

结论

我院肿瘤患者使用的化疗药物致吐风险等级主要为中、高风险，在止吐方案、药物经济性等方面存在不合理情况。建议医生、护士、临床药师及医院相关部门应多团队协作，加强止吐药物用药标准化全程监管，根据抗肿瘤药物致吐风险等级合理选择止吐药物，提高对指南的遵循度，以保障患者用药安全、有效、经济。

Abstract

OBJECTIVE

To provide reference for the rational use of antiemetic drugs in tumor chemotherapy patients.

METHODS

The data of tumor patients who were given antiemetic drugs were collected from 9 departments of our hospital with hospital information system from Oct. 1st to Nov. 30th in 2022， such as oncology department， radiotherapy department， gynecology department， and gastroenterology department. The application of chemotherapy drugs and the use of antiemetic drugs were analyzed statistically， and the irrational use of antiemetic drugs was analyzed.

RESULTS

A total of 520 patients were included， involving 248 （47.69%） using chemotherapy drugs with a moderate emetogenic risk level and 135 （25.96%） with a high emetogenic risk level. A total of 461 cases （73.06%） of 5-hydroxytryptamine 3-receptor antagonists were used， including palonosetron in 333 cases， ondansetron in 106 cases， tropisetron in 15 cases and granisetron in 7 cases， and only 148 cases of patients were prioritized for the use of nationally procured medicines and national essential medicines （32.10%）. Neurokinin-1 receptor antagonists were used in 170 cases （26.94%）， including fosaprepitant in 112 cases and aprepitant in 58 cases. The use of antiemetic drugs was unreasonable in 162 patients （31.15%）； among the types of irrational drugs， the antiemetic regimen was unreasonable in the largest number of cases （22.40%）， followed by the irrational pharmacoeconomics （19.13%）.

CONCLUSIONS

The emetogenic risk levels of chemotherapy drugs used for tumor patients in our hospital are primarily moderate to high， and there is irrational use of antiemetic regimen and pharmacoeconomics. Clinicians， nurses， pharmacists and hospital departments should collaborate as multiple teams to strengthen full supervision of the standardization of antiemetic drugs， reasonably select antiemetic drugs based on emetogenicity rating， and improve the compliance of doctors with the guidelines to ensure the safety， effectiveness， and cost-effective of patient medication.

关键词

止吐药物致吐风险等级合理用药化疗所致恶心呕吐肿瘤

Keywords

emetogenicity ratingrational drug usechemotherapy-induced nausea and vomitingtumor

references

中国药学会医院药学专业委员会，《化疗所致恶心呕吐的药物防治指南》编写组，张玉. 化疗所致恶心呕吐的药物防治指南[J]. 中国医院药学杂志，2022，42（5）：457-473.

Hospital Pharmacy Committee of Chinese Pharmaceutical Association，Writing Group of Guideline for Drug Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting，ZHANG Y.Guideline for drug prevention and treatment of chemotherapy-induced nausea and vomiting[J]. Chin J Hosp Pharm，2022，42（5）：457-473.

RAZVI Y，CHAN S，MCFARLANE T，et al. ASCO，NCCN，MASCC/ESMO：a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients[J]. Support Care Cancer，2019，27（1）：87-95.

LORUSSO D，BRIA E，COSTANTINI A，et al. Patients’ perception of chemotherapy side effects：expectations，doctor-patient communication and impact on quality of life：an Italian survey[J]. Eur J Cancer Care，2017，26（2）：e12618.

中国抗癌协会肿瘤临床化疗专业委员会，中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物治疗相关恶心呕吐防治专家共识：2022年版[J]. 中华医学杂志，2022，102（39）：3080-3094.

Committee of Clinical Chemotherapy，China Anti-cancer Association，Committee of Neoplastic Supportive-care，China Anti-cancer Association. Expert consensus on prevention and treatment of nausea and vomiting related to cancer drug treatment in China：2022 edition[J]. Natl Med J China，2022，102（39）：3080-3094.

程颖，柳菁菁. 《中国肿瘤药物治疗相关恶心呕吐防治专家共识（2022年版）》解读[J]. 临床内科杂志，2023，40（5）：351-353.

CHENG Y，LIU J J. Interpretation of Expert Consensus on Prevention and Treatment of Nausea and Vomiting Related to Cancer Drug Therapy in China：2022 Edition[J]. J Clin Intern Med，2023，40（5）：351-353.

唐慕菲，李园园. 肿瘤初次化疗预防恶心呕吐用药合理性分析[J]. 药学与临床研究，2021，29（6）：458-461.

TANG M F，LI Y Y. Analysis of rationality of drugs used to prevent nausea and vomiting in cancer patients under-going primary chemotherapy[J]. Pharm Clin Res，2021，29（6）：458-461.

林平，张威，甄健存. 全国87家医院2012—2014年肿瘤患者止吐药使用情况分析[J]. 中国药房，2017，28（11）：1470-1474.

LIN P，ZHANG W，ZHEN J C. Analysis of the utilization of antiemetics in cancer patients of 87 hospitals from 2012 to 2014[J]. China Pharm，2017，28（11）：1470-1474.

NAVARI R M，AAPRO M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting[J]. N Engl J Med，2016，374（14）：1356-1367.

MELLIN C，LEXA M，LEAK BRYANT A，et al. Antiemetic guidelines：using education to improve adherence and reduce incidence of CINV in patients receiving highly emetogenic chemotherapy[J]. Clin J Oncol Nurs，2018，22（3）：297-303.

张建盼，卢钧雄，钟艺，等. 外科药师参与化疗相关性恶心呕吐的管理实践[J]. 今日药学，2023，33（1）：49-52.

ZHANG J P，LU J X，ZHONG Y，et al. Surgical pharmacist involvement in the management of chemotherapy-induced nausea and vomiting in practice[J]. Pharm Today，2023，33（1）：49-52.

张慕华，王匀，陈嘉宁，等. CINV规范化治疗病房建设中临床药师工作模式的建立与成效研究[J]. 中国处方药，2022，20（8）：58-60.

ZHANG M H，WANG Y，CHEN J N，et al. Study on the establishment and effectiveness of clinical pharmacists working mode in the construction of CINV standardized treatment wards[J]. J China Prescr Drug，2022，20（8）：58-60.

朱志翔，王燕婷，杨珺. 我国肿瘤临床药师工作现状与分析[J]. 临床药物治疗杂志，2019，17（8）：70-73.

ZHU Z X，WANG Y T，YANG J. Current situation and analysis of oncology clinical pharmacists in China[J]. Clin Med J，2019，17（8）：70-73.

卢钧雄，张建盼，陈晓娜，等. 消化道肿瘤术后化疗相关性恶心呕吐防治的信息化外科药学实践[J]. 中国医院药学杂志，2023，43（7）：795-798，812.

LU J X，ZHANG J P，CHEN X N，et al. Informatized surgical pharmacy practice for the prevention and treatment of chemotherapy-related nausea and vomiting after gastrointestinal tumor surgery[J]. Chin J Hosp Pharm，2023，43（7）：795-798，812.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

肿瘤联合化疗与用药顺序

肿瘤相关性抑郁的治疗药物研究进展

二甲双胍的临床应用新进展Δ

参麦注射液辅助化疗治疗恶性肿瘤疗效的Meta分析

药物基因组学在肿瘤化疗中的应用与研究进展

Related Author

王程程彭　媛陈芙蓉张志勇

张连军丁兆生

李星霞余　奇郭　澄

朱亚兰郭佳奕包美蓉

熊萱张远边原

廖君孔佩艳

杜娟赵秀莉刘琳

林能明

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰